Due to recent advantages in cancer therapy, immune checkpoint inhibitors (ICIs) are new classes of drugs targeting programmed cell death protein 1 (PD-1) or its ligand programmed cell death protein 1-ligand 1 (PD-L1, synonym CD274, B7 homolog 1) and are used in many cancer therapies (1). Here, PDCD1 is linked to cancer.